Critical Limb Ischemia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Critical Limb Ischemia Clinical Trial Analysis research report provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top-line data relating to the clinical trials on Critical Limb Ischemia. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials.
What is the regional and country-wise outlook in the Critical Limb Ischemia clinical trials market?
The Critical Limb Ischemia clinical trials market is the largest in Asia Pacific, followed by Europe, North America, the Middle East and Africa, and South and Central America. In a country-wise analysis, as of May 2022, the US has the highest number of Critical Limb Ischemia clinical trials, followed by Japan, China, Germany, India, Russia, Spain, Netherlands, Italy, and South Korea. Germany has the highest average patient enrollment in Critical Limb Ischemia clinical trials.
G7 countries:
Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Japan has the highest proportion of Critical Limb Ischemia to cardiovascular clinical trials. Moreover, out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries:
Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, India has the highest proportion of Critical Limb Ischemia to Cardiovascular clinical trials. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Critical Limb Ischemia clinical trials market, by region
For more regional insights, download a free report sample
What are the key sponsor types in the Critical Limb Ischemia clinical trials market?
The key sponsor types in the Critical Limb Ischemia clinical trials market are institution, company, and government. Out of them, institution dominates the market.
Critical Limb Ischemia clinical trials market, by sponsor types
For more sponsor type insights, download a free report sample
Which are the key companies in the Critical Limb Ischemia clinical trials market?
The key companies in the Critical Limb Ischemia clinical trials market are AnGes Inc, Pluristem Therapeutics Inc, Mercator MedSystems Inc, Stempeutics Research Pvt Ltd, Reven Holdings Inc, United Therapeutics Corp, ThermoGenesis Holdings Inc, Sanofi, Beijing Northland Biotech Co Ltd, and Bayer AG.
Critical Limb Ischemia clinical trials market, by companies
To know more about companies, download a free report sample
Market report overview
Key regions | Asia-Pacific, Europe, Northern America, Middle East and Africa, and South and Central America |
Key countries | The US, Japan, China, Germany, India, Russia, Spain, Netherlands, Italy, and South Korea |
Key sponsor types | Institution, Company, and Government |
Key companies | AnGes Inc, Pluristem Therapeutics Inc, Mercator MedSystems Inc, Stempeutics Research Pvt Ltd, Reven Holdings Inc, United Therapeutics Corp, ThermoGenesis Holdings Inc, Sanofi, Beijing Northland Biotech Co Ltd, and Bayer AG |
Scope
The report provides:
- A snapshot of the global clinical trials landscape.
- Top level data related to the clinical trials by region, country, trial status, trial phase, sponsor type, and end point status.
- Reviews of top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company.
- All the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- Enrollment trends for the past five years.
- Latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Mercator MedSystems Inc
Pluristem Therapeutics Inc
Stempeutics Research Pvt Ltd
Reven Holdings Inc
Bayer AG
Beijing Northland Biotech Co Ltd
Sanofi
ThermoGenesis Holdings Inc
United Therapeutics Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key regions in the Critical Limb Ischemia clinical trials market?
The key regions in the Critical Limb Ischemia clinical trials market are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
-
What are the key countries in the Critical Limb Ischemia clinical trials market?
The key countries in the Critical Limb Ischemia clinical trials market are the US, Japan, China, Germany, India, Russia, Spain, Netherlands, Italy, and South Korea.
-
What are the key sponsor types in the Critical Limb Ischemia clinical trials market?
The key sponsor types in the Critical Limb Ischemia clinical trials market are institution, company, and government.
-
Which are the key companies in the Critical Limb Ischemia clinical trials market?
The key companies in the Critical Limb Ischemia clinical trials market are AnGes Inc, Pluristem Therapeutics Inc, Mercator MedSystems Inc, Stempeutics Research Pvt Ltd, Reven Holdings Inc, United Therapeutics Corp, ThermoGenesis Holdings Inc, Sanofi, Beijing Northland Biotech Co Ltd, and Bayer AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.